WY 14,643 inhibits human aldose reductase activity

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 21, Issue 5, 2006, Pages 569-573

  Klemin, Sara ^a   Calvo, Richard Y ^a   Bond, Stephanie ^a   Dingess, Heather ^a   Rajkumar, Balakrishnan ^a   Perez, Rachel ^a   Chow, Lucy ^a   Balendiran, Ganesaratnam K ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Aldose reductase; Diabetes; Glucose; Inhibition; Pirinixic acid; Polyol; PPAR; Sorbitol; WY 14,643

Indexed keywords

ALCOHOL; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIRINIXIC ACID;

ALCOHOL OXIDATION; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

ALDEHYDE REDUCTASE; BENZYL ALCOHOL; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PYRIMIDINES;

EID: 33751088003     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360600720887     Document Type: Article

References (36)

1. Tomlinson, DR and Stevens, EJ and Diemel, LT. (1994) Aldose reductase inhibitors and their potential for the treatment of diabetic complications Trends Pharmacol Sci., 15, pp. 293-297.
2. Gabbay, KH. (1973) The sorbitol pathway and the complications of diabetes N Engl J Med., 288, pp. 831-836.
3. Jaspan, J. (1986) Pharmacological inhibition of aldose reductase in human diabetic neuropathy Drugs, 32(Suppl 2), pp. 23-29.
4. Brankston, ER and Corriveau, R and Laroche, C and Roy, R and Savard, C and Roy, D and Kelly, R and Forget, P and Rivard, M and Boulerice, F. (1998) Effect of AR inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy Clin Drug Invest., 15, pp. 111-121.
5. Hodgkinson, AD and Sondergaard, KL and Yang, B and Cross, DF and Millward, BA and Demaine, AG. (2001) Aldose reductase expression is induced by hyperglycemia in diabetic nephropathy Kidney Int., 60, pp. 211-218.
6. Galvez, AS and Ulloa, JA and Chiong, M and Criollo, A and Eisner, V and Barros, LF and Lavandero, S. (2003) Aldose reductase induced by hyperosmotic stress mediates cardiomyocyte apoptosis: Differential effects of sorbitol and mannitol J Biol Chem., 278, pp. 38484-38494.
7. Morrison, AD and Clements, RS, Jr and Travis, SB and Oski, F and Winegrad, AI. (1970) Glucose utilization by the polyol pathway in human erythrocytes Biochem Biophys Res Commun., 40, pp. 199-205.
8. Gonzalez, RG and Barnett, P and Aguayo, J and Cheng, HM and Chylack, LT, Jr. (1984) Direct measurement of polyol pathway activity in the ocular lens Diabetes, 33, pp. 196-199.
9. Kicic, E and Palmer, TN. (1996) Increased white cell aldose reductase mRNA levels in diabetic patients Diabetes Res Clin Pract., 33, pp. 31-36.
10. Kinoshita, JH and Nishimura, C. (1988) The involvement of aldose reductase in diabetic complications Diabetes Metab Rev., 4, pp. 323-337.
11. Pugliese, G and Tilton, RG and Williamson, JR. (1991) Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease Diabetes Metab Rev., 7, pp. 35-59.
12. Kawamura, M and Heinecke, JW and Chait, A. (1994) Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway J Clin Invest., 94, pp. 771-778.
13. Ramasamy, R and Oates, PJ and Schaefer, S. (1997) Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury Diabetes, 46, pp. 292-300.
14. Ramasamy, R and Trueblood, N and Schaefer, S. (1998) Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion Am J Physiol., 275, pp. H195-H203.
15. Oates, PJ and Mylari, BL. (1999) Aldose reductase inhibitors: Therapeutic implications for diabetic complications Expert Opin Investig Drugs, 8, pp. 2095-2119.
16. Young, LH and Russell, RR and Chyun, DA and Ramahi, T.(2001) In Diabetes and Cardiovascular Disease. Totowa, NJ: Humana Press. Totowa, NJ
17. Kannel, WB and Hjortland, M and Castelli, WP. (1974) Role of diabetes in congestive heart failure: The framingham study Am J Cardiol., 34, pp. 29-34.
18. Levy, D and Larson, MG and Vasan, RS and Kannel, WB and Ho, KK. (1996) The progression from hypertension to congestive heart failure JAMA, 275, pp. 1557-1562.
19. Jaffe, AS and Spadaro, JJ and Schechtman, K and Roberts, R and Geltman, EM and Sobel, BE. (1984) Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus Am Heart J., 108, pp. 31-37.
20. Nesto, RW and Zarich, S. (1998) Acute myocardial infarction in diabetes mellitus: Lessons learned from ACE inhibition Circulation, 97, pp. 12-15.
21. Bradford, MM. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem., 72, pp. 248-254.
22. Nishimura, C and Yamaoka, T and Mizutani, M and Yamashita, K and Akera, T and Tanimoto, T. (1991) Purification and characterization of the recombinant human aldose reductase expressed in baculovirus system Biochim Biophys Acta., 1078, pp. 171-178.
23. Liu, SQ and Bhatnagar, A and Srivastava, SK. (1992) Does sorbinil bind to the substrate binding site of aldose reductase? Biochem Pharmacol, 44, pp. 2427-2429.
24. Balendiran, GK and Rajkumar, B. (2005) Fibrates inhibit aldose reductase activity in the forward and reverse reactions Biochem Pharmacol., 70, pp. 1653-1663.
25. Tracey, WR and Magee, WP and Ellery, CA and MacAndrew, JT and Smith, AH and Knight, DR and Oates, PJ. (2000) Aldose reductase inhibition alone or combined with an adenosine A(3) agonist reduces ischemic myocardial injury Am J Physiol Heart Circ Physiol., 279, pp. H1447-H1452.
26. Hwang, YC and Sato, S and Tsai, JY and Yan, S and Bakr, S and Zhang, H and Oates, PJ and Ramasamy, R. (2002) Aldose reductase activation is a key component of myocardial response to ischemia FASEB J., 16, pp. 243-245.
27. Trueblood, N and Ramasamy, R. (1998) Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts Am J Physiol., 275, pp. 75-83.
28. Trueblood, NA and Ramasamy, R and Wang, LF and Schaefer, S. (2000) Niacin protects the isolated heart from ischemia-reperfusion injury Am J Physiol Heart Circ Physiol., 279, pp. H764-H771.
29. Stanley, WC and Lopaschuk, GD and Hall, JL and McCormack, JG. (1997) Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions Cardiovasc Res., 33, pp. 243-257.
30. Taegtmeyer, H and King, LM and Jones, BE. (1998) Energy substrate metabolism, myocardial ischemia, and targets for pharmacotherapy Am J Cardiol., 82, pp. 54K-60K.
31. Kagaya, Y and Kanno, Y and Takeyama, D and Ishide, N and Maruyama, Y and Takahashi, T and Ido, T and Takishima, T. (1990) Effects of long-term pressure overload on regional myocardial glucose and free fatty acid uptake in rats. A quantitative autoradiographic study Circulation, 81, pp. 1353-1361.
32. Allard, MF and Schonekess, BO and Henning, SL and English, DR and Lopaschuk, GD. (1994) Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts Am J Physiol., 267, pp. H742-H750.
33. Doenst, T and Goodwin, GW and Cedars, AM and Wang, M and Stepkowski, S and Taegtmeyer, H. (2001) Load-induced changes in vivo alter substrate fluxes and insulin responsiveness of rat heart in vitro Metabolism, 50, pp. 1083-1090.
34. Barger, PM and Kelly, DP. (2000) PPAR signaling in the control of cardiac energy metabolism Trends Cardiovasc Med., 10, pp. 238-245.
35. Aoyama, T and Peters, JM and Iritani, N and Nakajima, T and Furihata, K and Hashimoto, T and Gonzalez, FJ. (1998) Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha) J Biol Chem., 273, pp. 5678-5684.
36. Wayman, NS and Hattori, Y and McDonald, MC and Mota-Filipe, H and Cuzzocrea, S and Pisano, B and Chatterjee, PK and Thiemermann, C. (2002) Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size FASEB J., 16, pp. 1027-1040.